Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4 + CD25 + FoxP3 + T reg cells in vivo

International Immunopharmacology

Volumn 11, Issue 11, 2011, Pages 1802-1808

  Farsam, Vida ^a   Hassan, Zuhair Muhammad ^a   Zavaran Hosseini, Ahmad ^a   Noori, Shokoofe ^b   Mahdavi, Mehdi ^c   Ranjbar, Moslem ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antitumor; Breast cancer; Immunomodulator; Regulatory T cells

Indexed keywords

ARTEMETHER; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES, REGULATORY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80055020917     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.07.008     Document Type: Article

References (44)

1. P. Porter Global trends in breast cancer incidence and mortality Salud Publica Mex 51 2009 141 146
2. B. Gerber, M. Freund, and T. Reimer Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life 2010
3. J. Gibbs Mechanism-based target identification and drug discovery in cancer research Science 287 2000 1969 1973 (Pubitemid 30158664)
4. R.H. Bradbury Cancer Top Med Chem 1 2007
5. I. Nakase, H. Lai, N. Singh, and T. Sasaki Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation Int J Pharm 345 1-2 2008 28 33 (Pubitemid 351400327)
6. H. Chen, H. Zhou, and X. Fang Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro Pharmacol Res 48 2003 231 236 (Pubitemid 36818928)
7. H. Lai, and N. Singh Selective cancer cell cytotoxicity from exposure in dihydroartemisinin and holotransferrin Cancer Lett 91 1995 41 46
8. N. Singh, and V. Panwar Case report of a pituitary macroadenoma treated with artemether Integr Cancer Ther 5 4 2006 391
9. D. Klayman Qinghaosu (artemisinin): an antimalarial drug from China Science 228 1985 1049 1055 (Pubitemid 15227365)
10. V. Dhingra, R. Vishweshwar, and N. Lakshmi Current status of artemisinin and its derivatives as antimalarial drugs Life Sci 66 4 1999 279 300
11. A. Robert, F. Benoit-Vical, and B. Meunier The key role of heme to trigger the antimalarial activity of trioxanes Coord Chem Rev. 249 17-18 2005 1927 1936 (Pubitemid 41121959)
12. M.A. van Agtmael, V. Gupta, T.H. van der Wösten, J.P.B. Rutten, and C.J. van Boxtel Grapefruit juice increases the bioavailability of artemether Eur J Clin Pharmacol 55 1999 405 410 (Pubitemid 29344086)
13. K. Silamut, P.N. Newton, P. Teja-Isavadharm, Y. Suputtamongkol, D. Siriyanonda, and M. Rasameesoraj Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria Antimicrob Agents Chemother 47 12 December 1 2003 3795 3798 (Pubitemid 37484991)
14. M. van Agtmael, T. Eggelte, and C. van Boxtel Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication Trends Pharmacol Sci 20 5 1999 199 205
15. T. Efferth, M. Romero, D. Wolf, T. Stamminger, J. Marin, and M. Marschall The antiviral activities of artemisinin and artesunate Clin Infect Dis 47 2008 804 811
16. S. Kumar, S. Khanuja, T. Kumar, D. Jain, S. Srivastava, and A. Bhattacharya Method for the use of alpha artemether as an anti-bacterial and anti-fungal agent 2000 Google Patents
17. A. Galal, S. Ross, M. Jacob, and M. ElSohly Antifungal activity of artemisinin derivatives J Nat Prod 68 8 2005 1274 1276 (Pubitemid 41291279)
18. D. Yang, and F. Liew Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis Parasitology 106 01 2009 7 11
19. Z. Wu, C. Gao, Y. Wu, and Q. Zhu Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model Integr Cancer Ther 8 1 2009 88
20. J. Golenser, J. Waknine, M. Krugliak, N. Hunt, and G. Grau Current perspectives on the mechanism of action of artemisinins Int J Parasitol 36 14 2006 1427 1441 (Pubitemid 44751746)
21. A. Ghantous, H. Gali-Muhtasib, H. Vuorela, N.A. Saliba, and N. Darwiche What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 15 15-16 2010 668 678
22. Y. Hwang, H. Yun, H. Kim, E. Han, G. Lee, and H. Jeong Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCa/Raf/MAPKs and NF-kB/AP-1-dependent mechanisms Biochem Pharmacol 79 2010 1714 1726
23. C. Morrissey, B. Gallis, J.W. Solazzi, B.J. Kim, R. Gulati, and F. Vakar-Lopez Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells Anticancer Drugs 21 4 2010 423 432
24. V. Konkimalla, M. Blunder, B. Korn, S. Soomro, H. Jansen, and W. Chang Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW264.7 mouse macrophage cells Nitric Oxide 19 2008 184 191
25. O. Finn Molecular origins of cancer: cancer immunology N Engl J Med 2008 2704 2715 (Pubitemid 351860863)
26. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 6 2008 1991
27. C.M. Barbon, M. Yang, G.D. Wands, R. Ramesh, B.S. Slusher, and M.L. Hedley Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization Cell Immunol 262 2 2010 150 161
28. S. Wada, K. Yoshimura, E. Hipkiss, T. Harris, H. Yen, and M. Goldberg Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model Cancer Res 69 10 2009 4309
29. + regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 5 2007 641 648 (Pubitemid 46348738)
30. L. Zitvogel, A. Tesniere, and G. Kroemer Cancer despite immunosurveillance: immunoselection and immunosubversion Nat Rev Immunol 6 10 2006 715 727 (Pubitemid 44453458)
31. J. Wang, W. Tang, L. Shi, J. Wan, R. Zhou, and J. Ni Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation Br J Pharmacol 150 5 2007 652 661 (Pubitemid 46355561)
32. J. Wang, W. Tang, Z. Yang, J. Wan, L. Shi, and Y. Zhang Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo Eur J Pharmacol 564 1-3 2007 211 218 (Pubitemid 46957514)
33. S. Yang, S. Xie, H. Gao, and Z. Long Artemisinin and its derivatives enhance T lymphocyte-mediated immune responses in normal mice and accelerate immunoreconstitution of mice with syngeneic bone marrow transplantation Clin Immunol Immunopathol 69 2 1993 143 148 10.1006/clin.1993.1162 (Pubitemid 23319380)
34. S.X. Yang, S.S. Xie, D.L. Ma, H.L. Gao, and Z.Z. Long Enhancement of interleukin-2 production and its mRNA expression by dihydroartemisinin Acta Pharmacol Sin 15 6 1994 515 520
35. L. Langroudi, Z.M. Hassan, M. Ebtekar, M. Mahdavi, N. Pakravan, and S. Noori A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model Int Immunopharmacol 10 2010 1055 1061
36. M. Ebtekar, and Z. Hassan Effect of immunomodulators pyrimethamine and cimetidine on immunosuppression induced by sulfur mustard in mice Int J Immunopharmacol 15 4 1993 533 541 (Pubitemid 23179280)
37. Z.M. Hassan, R. Yaraee, N. Zare, T. Ghazanfari, A.H. Sarraf Nejad, and B. Nazori Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity Int Immunopharmacol 3 10-11 2003 1483 1489 (Pubitemid 37025729)
38. M. Liu, M.S. Bryant, J. Chen, S. Lee, B. Yaremko, and P. Lipari Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice Cancer Res 58 21 November 1 1998 4947 4956 (Pubitemid 28503695)
39. I. Witz, and O. Levy-Nissenbaum The tumor microenvironment in the post-PAGET era Cancer Lett 242 2006 1 10 (Pubitemid 44485302)
40. D. Vignali, L. Collison, and C. Workman How regulatory T cells work Nat Rev Immunol 8 7 2008 523 532
41. T. Curiel Tregs and rethinking cancer immunotherapy J Clin Invest 117 2007 1167 1174 (Pubitemid 46718401)
42. X. Cao, S. Cai, T. Fehniger, J. Song, L. Collins, and D. Piwnica-Worms Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance Immunity 27 4 2007 635 646 (Pubitemid 47628832)
43. W. Niedbala, B. Cai, H. Liu, N. Pitman, L. Chang, and F.Y. Liew Nitric oxide induces CD4 CD25 Foxp3 regulatory T cells from CD4 CD25 T cells via p53, IL-2, and OX40 PNAS 104 39 2007 15478 15483
44. S. Noori, M. Taghikhani, Z.M. Hassan, A. Allameha, and A. Mostafaei Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo Mol Immunol 47 7-8 2010 1579 1584